<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03653260</url>
  </required_header>
  <id_info>
    <org_study_id>2016-ZK-007</org_study_id>
    <nct_id>NCT03653260</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Zingo in Chinese Children</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety in Chinese Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lee's Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhaoke (Hefei) Pharmaceutical Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lee's Pharmaceutical Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of Zingo in treating pain
      associated with venipunture and peripheral venous cannulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 15, 2018</start_date>
  <completion_date type="Actual">May 21, 2019</completion_date>
  <primary_completion_date type="Actual">February 28, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wong-Baker FACES Pain Rating Scale After Venipuncture or Peripheral Cannulation</measure>
    <time_frame>immediate after venipunture</time_frame>
    <description>Child's assessment of pain on venipuncture or peripheral venous cannulation (all ages) performed one to three minutes after Zingo/Placebo administration, measured using the Wong-Baker FACES pain rating scale. The scale includes pictures of facial expressions with correlating numerical scale of 0-10, 0 being no hurt and 10 being the worst hurt.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>100-mm Visual Analogue Scale (VAS)</measure>
    <time_frame>immediate after venipunture</time_frame>
    <description>Assessment of pain on venipuncture or peripheral venous cannulation by children age 8-12, measured using a 100-mm VAS (0-100) anchored at 0 for &quot;no pain&quot; and at 100 for &quot;worst possible pain.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>immediate after venipunture</time_frame>
    <description>Percentage of subject who score 0 or 1 in the FACES Pain Rating Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance Score</measure>
    <time_frame>immediate after venipunture</time_frame>
    <description>Compliance to venipuncture assess by investigator</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Event Frequency</measure>
    <time_frame>1 day</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Event Severity</measure>
    <time_frame>1 day</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Comfort of Zingo/Placebo Administration (Wong-Baker)</measure>
    <time_frame>immediate after venipunture</time_frame>
    <description>Subject (all ages) to assess the level of comfort of Zingo/Placebo administration, measured using the Wong-Baker FACES scale (0-10), where 0 represent No Discomfort and 10 represent Worst Possible Discomfort.</description>
  </other_outcome>
  <other_outcome>
    <measure>Comfort of Zingo/Placebo Administration (VAS)</measure>
    <time_frame>immediate after venipunture</time_frame>
    <description>Subject (age 8-12) to assess the level of comfort of Zingo/Placebo administration, measured using VAS pain rating scales (0-100), where 0 represent No Discomfort and 100 represent Worst Possible Discomfort.</description>
  </other_outcome>
  <other_outcome>
    <measure>Local Adverse Reaction</measure>
    <time_frame>Pre-dose (0-1 hour before), immediately after dose, 15 minutes, 30 minutes</time_frame>
    <description>Local Adverse Reactions including erythema, edema, pruritus and hemorrhage/petechiae by severity.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">288</enrollment>
  <condition>Catheter Site Pain</condition>
  <condition>Pain, Acute</condition>
  <condition>Anesthesia, Local</condition>
  <arm_group>
    <arm_group_label>Lidocaine (Zingo)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5mg lidocaine at 20 bar pressure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>no emitted particle at 20 bar pressure, identical in external appearance to Zingo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine (Zingo)</intervention_name>
    <description>0.5 mg lidocaine, 20 bar pressure</description>
    <arm_group_label>Lidocaine (Zingo)</arm_group_label>
    <other_name>Zingo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo injector, 20 Bar pressure, empty injector</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged 3-12

          -  About to undergo venipuncture or peripheral venous cannulation at the back of the hand
             or antecubital fossa

          -  Have sufficient cognitive skills to identify faces depicting extremes of pain on the
             Wong-Baker FACES scale (age 3-12) and the extremes of pain on a 100 mm visual analog
             scale (VAS) (ages 8-12)

          -  Signed informed consent, cooperative and agree to attend follow-up visits

        Exclusion Criteria:

          -  Any medical condition, non-compliance or instability (including but not limited to
             exceptionally upset, crying, anxiety) that in the judgement of the investigator might
             adversely affect the conduct of the study

          -  Used any (including external or inhaled) sedatives, analgesics, anaesthetics or other
             agents/device that may affect the efficacy assessment

          -  Subjects with tattoos, surgical scars, ports, implantable devices or a skin condition
             (e.g. excessive body hair) that may have interfered with the placement of Zingo or
             skin site assessments

          -  Active local infection or other skin pathology at the site of venipuncture or
             peripheral venous cannulation.

          -  Venipuncture of peripheral venous cannulation at the proposed site within the prior
             two weeks (longer if the wound is apparent)

          -  Previous history of allergic reactions to any local anaesthetic or tape/adhesive
             dressing.

          -  Participated in a clinical trial within three months prior to administration of study
             drug, or have already enrolled in a Zingo clinical trial before

          -  At the discretion of the investigator, any subjects that may have to be withdrawn from
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mazhong Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Children's Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Children's Medical Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 28, 2018</study_first_submitted>
  <study_first_submitted_qc>August 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>September 23, 2019</last_update_submitted>
  <last_update_submitted_qc>September 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

